NASDAQ$QDEL
Quidel Corp · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
QuidelOrtho reported total revenues of $613.9 million and a net loss of $255.4 million for the second quarter of 2025.
The company posted a quarterly net loss driven by significant restructuring, integration and other charges of $178.9 million, including costs related to the Savanna Exit and Optimization Plan. Revenues declined 4% year-over-year primarily due to lower Point of Care and Donor Screening sales, partially offset by growth in Labs and Immunohematology. Operating loss widened to $180.7 million amid these one-time charges.
- Total revenues of $613.9 million declined 4% from the prior year quarter due to lower respiratory and donor screening sales.
- Net loss of $255.4 million included $178.9 million in restructuring and integration charges.
- Labs revenue grew 4% to $369.7 million while Point of Care revenue fell 21%.
- North America revenues decreased 11% to $310.7 million, while EMEA and China showed modest growth.
Headline financials
Revenue & EPS history
Quidel · Revenue · Quarterly
$614M
Revenue by segment
Quidel · $614M total across 5 segments · Q2 2025
- Labs$370M—60.2%
- Immunohematology$132M—21.6%
- Point of Care$93M—15.1%
- Donor Screening$13.3M—2.2%
- Molecular Diagnostics$5.6M—0.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
-3.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
17%
2 / 12 earnings
Positive
+6.9%
Q2 2024
Best reaction
-17.6%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -6.0% | -14.8% | +22.8% | |
| Q4 2025 | -17.6% | -19.7% | -40.6% | |
| Q3 2025 | -4.3% | +6.3% | +30.6% | |
| Q1 2025 | -0.3% | +44.3% | +13.8% | |
| Q3 2024 | -2.8% | +3.0% | -4.4% | |
| Q2 2024 | +6.9% | +2.0% | +7.5% | |
| Q1 2024 | -2.7% | -4.0% | -5.0% | |
| Q3 2023 | -0.9% | +2.9% | +13.3% | |
| Q2 2023 | -2.0% | -7.1% | -9.8% | |
| Q1 2023 | -6.5% | -7.7% | -7.6% | |
| Q3 2022 | +3.8% | +0.1% | +7.7% | |
| Q2 2022 | -5.1% | -6.3% | -19.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro